Navigation Links
India's Non-Small-Cell Lung Cancer Drug Market Will Almost Double by 2013
Date:5/13/2009

Western Branded Drug Sales Will Command 54 percent of the Market by 2013, According to a New Report from Decision Resources

WALTHAM, Mass., May 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the non-small-cell lung cancer drug market in India will almost double by 2013, growing from $27.7 million in 2008 to $52.1 million in 2013. This growth will be fueled by an increased uptake of antimetabolites and targeted therapies. In fact, the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitor drug classes will dominate the market throughout the forecast period with a combined market share of 55 percent by 2013.

The new Emerging Markets report entitled Non-Small-Cell Lung Cancer in India also finds that Western-branded drug sales in India's non-small-cell lung cancer market will command 54 percent by 2013. Even though Western-branded small-molecule agents are facing fierce competition from domestic products, including gefitinib (in the U.S. known as AstraZeneca's Iressa) and erlotinib (in the U.S. known as Genentech's Tarceva), future opportunities for Western companies will depend heavily on their pricing strategies and their patent protection in India. Moreover, monoclonal antibodies will surge and won't be copied successfully during the report's 2008 - 2013 forecast period.

"Opportunity for Western companies penetrating or wanting to penetrate India's non-small-cell lung cancer (NSCLC) drug market lies in forming alliances with Indian companies in order to negotiate the complex regulatory process of getting new NSCLC therapies to market," stated Manashi Sherawat, Ph.D., analyst at Decision Resources. "Opportunity also lies in raising awareness of this form of cancer in India's urban and rural sectors."

About Emerging Markets Reports

Emerging Markets is a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Natalia Morales                              Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    nmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
2. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
3. Survival differences by race most apparent in advanced stages of breast cancer
4. MRI finds breast cancer before it becomes dangerous
5. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
6. Pathway links inflammation, angiogenesis and breast cancer
7. Radiologists encouraged to look beyond cancer for clinically unseen diseases
8. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
9. Immune deficiency linked to a type of eye cancer
10. Drop in breast cancer incidence linked to hormone use, not mammograms
11. Breast cancer prevention practices vary across Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... ... Curl Keeper® is excited to announce that the H2O Water Bottle is the ... second year in a row. The H2O Bottle, a refillable ultra-fine spray water bottle ... Type 2 Wavies and Best Refresher for Type 2 Wavies in 2017. , ...
(Date:8/19/2017)... , ... August 19, 2017 , ... “Congratulations! It's A ... of children to both their parents and God. “Congratulations! It's A Boy! God’s Gift: ... Anthony, a couple from Long Island, New York. , Published by Christian Faith Publishing, ...
(Date:8/18/2017)... NY (PRWEB) , ... August 18, 2017 , ... ... of “Vision & Hearing” campaign, advocating for active, healthy lifestyles and highlighting the ... available for individuals with hearing impairments and shares the latest innovations in hearing ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... financial consultations to communities throughout the greater DC region, is inaugurating a “New ... of rescuing local animals and training them to be companions for veterans in ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... firm that serves residential and commercial clients in the greater Houston region, is ... community support for the fight against cancer. , Founded by Tony and Amber ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... July 31, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), has ... Michigan by Crain,s Detroit Business . ... public companies by three-year revenue growth. This year,s edition measures ... To view the complete list, visit crainsdetroit.com/awards/fast_50/2017 .  ... an incredible triumph," said Phil Hagerman , CEO and ...
(Date:7/31/2017)... 2017 7D Surgical, developer of ground breaking surgical ... 7D Surgical System to support its strategic sales plan in ... and Virginia.  7D Surgical has entered into an exclusive ... premier medical facilities within those markets. ... Spartan Medical ...
(Date:7/28/2017)... 28, 2017 EnvoyHealth, a Diplomat company, has partnered ... for CleverCap LITE, a technology designed to improve patient ... innovative health technology solutions and services that help track ... CleverCap LITE offers medication monitoring and control ... Records date and ...
Breaking Medicine Technology: